Our board comprise member with both industry specific experience and business understanding, and have all a long track record of current and previous executive- and board positions.
- Board of directors
Board of directors
Jònas Einarsson has been the Chairman of the Board since 2018 and has served as a Board Member since 2011. Mr. Einarsson has over 30 years of experience in the medical industry and has had and has several board positions in Norwegian biotech companies. He is currently the CEO of Radforsk Investment Fund, which position he has held since 2000. Mr. Einarsson was a general practitioner and health director of the Lardal municipality from 1991 until 2000 and was general manager of Oslo Private Hospital from 1984 until 1991.
Mr. Einarsson is educated as a Medical Doctor (MD) from the Reykjavik University, Iceland and the University of Oslo, Norway.
Leiv Askvig has served as a Board Member since 2015, and is currently also a member of the Audit Committee. Mr Askvig is an Investment Advisor for Sundt AS, and served as their CEO from 2003 to 2020. Mr Askvig has vast experience within the financial industry. He was CEO/CFO at Opticore AB from 2001 until 2002, CFO at StudentUniverse, Inc. from 1999 until 2001 and has held various positions within investment banking at Sundal Collier & Co ASA (now "ABG Sundal Collier"). Mr Askvig holds a bachelor degree in Business Administration from BI Norwegian Business School and attended the Advanced Management course at Harvard Business School.
Ketil Fjerdingen has served as a Board Member since 2012 and was the Chairman of the Board of Directors from 2012 until 2018. Mr. Fjerdingen has, since 2002, been involved in investments and property development projects through a range of small single purpose companies. Prior to this, he held various executive management roles with companies including VI Partners AS, Mobile Media, Ernst & Young and Fokus Bank ASA. Mr. Fjerdingen holds the degree of Certified Public Accountant from NHH Norwegian School of Economics.
Henrik Schüssler has served as a Board Member since 2015. Mr Schüssler is the CEO and board member of Gjelsten Holding AS, which position he has held since 2000. Mr Schüssler was CEO and CFO at Norway Seafoods ASA from 1995 until 2000 and accountant/consultant at Ernst & Young AS from 1987 until 1995.
Mr Schüssler holds a Bachelor of Chartered Accounting from BI Norwegian Business School.
Kari Grønås has served as a Board Member since 2019. Kari Grønås (1964) has broad experience from the pharmaceutical/biotech industry. She has extensive experience in drug development and commercialization within the pharmaceutical industry of new breakthrough products securing regulatory approvals, i.e. Xofigo, Hexvix. Grønås also holds significant leadership and management experience including leadership of cross functional and governance teams from Bayer/Algeta ASA, PhotoCure and Nycomed Imaging/Amersham Health (Now GE Healthcare). Today she is a consultant within the sector and holds board positions in Spago Nanomedical AB, Arxx AS and The Norwegian Lung Cancer Society. Ms Grønås hold s a Cand. Pharm. (M. Sci. Pharm) from the University of Oslo (UIO).
Eva S. Dugstad
Eva S. Dugstad has served as a Board Member since 2019. Ms. Dugstad started as Manager for Business and Community Relations at Faculty of Mathematics and Natural Sciences, University of Oslo, in February 2022. She then came from a position as Director for Business Development in Radforsk Investment Fund, a position she had held since 2017. Her previous appointments include the President and the Exec. Vice President at the Institute for Energy Technology (IFE), where she also was the chair of the board for IFE Venture. Ms. Dugstad has been involved in various boards in both public and private sector and in several public expert panels.
Ms. Dugstad holds a Cand. Pharm. degree from the University of Oslo.
Haakon Stenrød has served as a Board Member since 2020. Haakon Stenrød is a Senior Investment Manager at Watrium. Prior to joining Watrium, Mr Stenrød spent 12 years in the Investment Banking department of ABG Sundal Collier, focusing on M&A, restructurings and capital markets advisory. He is currently a Board member of DF Capital, a UK challenger bank listed on AIM London. In addition, he holds a Master in Industrial Economics and Technology management from NTNU, studied at London School of Economics and was an officer in the Royal Norwegian Army.
Aitana Peire has served as a Board Member since 2020. Ms. Peire is an Investment Director of Canica’s Future of Health assets and holds board positions in Hubro Therapeutics AS and Cercare Medical ApS (observer). She has wide experience as Industry Analyst, including as senior consultant in Venture Valuation Switzerland and as Pharma equity research analyst for Kepler Cheuvreux.
Ms. Peire holds a PhD in Evolutionary Genetics from the University of Groningen in the Netherlands.